TMCnet News
Jasper Therapeutics Announces Key Regulatory and Clinical AppointmentsLisa Pitt, Pharm.D., M.S.J. appointed Senior Vice President, Regulatory Affairs Shiguang Liu, M.D., Ph.D. appointed Vice President, Clinical Development REDWOOD CITY, Calif., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases, today announced the appointments of Lisa Pitt, Pharm.D., M.S.J. as Senior Vice President, Regulatory Affairs and Shiguang Liu, M.D., Ph.D. as Vice President, Clinical Development. “We are excited to have Lisa and Shiguang join us at Jasper following our merger with Kira Pharmaceuticals,” said Jeet Mahal, President and Chief Executive Officer of Jasper. “Lisa’s experience in regulatory affairs at multiple biotech companies and the FDA, along with Shiguang’s expertise in clinical development in rare diseases in renal and metabolic disorders are key additions as we move forward with the development of vensobafusp alfa (KP104), briquilimab and KP701 across a number of immune diseases.” Dr. Pitt brings over 25 years of experience in leading regulatory and medical affairs across both the industry and at the U.S. Food and Drug Administration (FDA). Most recently, she served as Vice President, Regulatory Affairs at Aiolos Bio prior to its acquisition by GlaxoSmithKline. Prior to that, she held regulatory affairs leadership roles at NorthSea Therapeutics, Horizon Therapeutics, and Viela Bio prior to its acquisition by Horizon Therapeutics. Dr. Pitt served as Senior Regulatory Health Project Manager at the FDA’s Center for Drug Evaluation & Research in the former Division of Gastroenterology and Inborn Errors Products, where she managed the review of Investigation New Drug (IND), New Drug Application (NDA), and Biologic License Application (BLA) submissions. Earlier in her career, she served in Regulatory Affairs roles at AstraZeneca, PAREXEL Consulting, and Novartis. She started her career in laboratory quality assurance roles at Alpharma and Cambidge Biotech. Dr. Pitt received her Pharm.D. from the University of Maryland School of Pharmacy, an M.S.J. from Seton Hall Law School, and a Bachelor degree in Biological Sciences from the University of Delaware, and completed a post-doctoral clinical pharmacy fellowship at Novartis. Dr. Liu joins after spending over a decade of progressive leadership roles in research and development, pharmacovigilance, and clinical development at Sanofi. Most recently, he served as Clinical Lead and Senior Clinical Research Director with a focus on rare diseases in renal and metabolic disorders and leadership in late-stage clinical trials and regulatory submissions. Prior to joining the biopharmaceutical industry, Dr. Liu held several academic appointments, including Assistant Professor at The Kidney Institute at the University of Kansas Medical Center, research faculty at the Duke University School of Medicine, and Visiting Fellow at the National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health (NIH). Earlier in his career, he was an Associate Professor and Attending Physician at the First Affiliated Hospital of Zhengzhou University Medical School, where he also completed his residency training. Dr. Liu received his M.D. from Zhengzhou University Medical School as well as an M.S. in Medicine and a Ph.D. in Cell Biology from the Chinese Academy of Medical Sciences and Peking Union Medical College. Material Inducement Grants About Jasper Contacts: Argot Partners (investors and media) 
|
